Eph receptors in breast cancer: Roles in tumor promotion and tumor suppression

Breast Cancer Research

Volumn 10, Issue 6, 2008, Pages

  Vaught, David ^a   Brantley Sieders, Dana M ^a   Chen, Jin ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPHRIN RECEPTOR;

BREAST TUMOR; DRUG ANTAGONISM; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, EPH FAMILY;

EID: 63849221730     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2207     Document Type: Review

References (74)

1. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008, 133:38-52. 10.1016/j.cell.2008.03.011, 18394988.
2. Pasquale EB. Developmental cell biology: Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005, 6:462-475. 10.1038/nrm1662, 15928710.
3. Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005, 5:149-157. 10.2174/1568009053765780, 15892616.
4. Brantley-Sieders D, Schmidt S, Parker M, Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 2004, 10:3431-3442. 10.2174/1381612043383160, 15544526.
5. Brantley-Sieders D, Chen J. Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis 2004, 7:17-28. 10.1023/B:AGEN.0000037340.33788.87, 15302992.
6. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol 2002, 3:475. 10.1038/nrm856, 12094214.
7. Nikolova Z, Djonov V, Zuercher G, Andres A, Ziemiecki A. Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J Cell Sci 111:2741-2751.
8. Munarini N, Jager R, Abderhalden S, Zuercher G, Rohrbach V, Loercher S, Pfanner-Meyer B, Andres AC, Ziemiecki A. Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J Cell Sci 2002, 115:25-37.
9. Kouros-Mehr H, Werb Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn 2006, 235:3404-3412. 10.1002/dvdy.20978, 17039550.
10. Andres A-C, Reid HH, Zurcher G, Blaschke RJ, Albrecht D, Ziemiecki A. Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene 1994, 9:1461-1467.
11. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000, 19:6043-6052. 10.1038/sj.onc.1204004, 11146556.
12. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001, 61:2301-2306.
13. Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE 2008, 3:e2994. 2500166, 18714348, 10.1371/journal.pone.0002994.
14. Fang WB, Ireton RC, Zhuang G, Takahashi T, Reynolds A, Chen J. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci 2008, 121:358-368. 10.1242/jcs.017145, 18198190.
15. Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, Yaswen P, Bissell MJ. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res 2006, 66:7095-7102. 10.1158/0008-5472.CAN-06-0515, 16849555.
16. Fox BP, Kandpal RP. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 2004, 318:882-892. 10.1016/j.bbrc.2004.04.102, 15147954.
17. Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 2004, 10:26-33. 10.1007/BF02893405, 15029258.
18. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J. Soluble EphA receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002, 21:7011-7026. 10.1038/sj.onc.1205679, 12370823.
19. Pan M. Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor status [ASCO Annual Meeting Proceedings]. J Clin Oncol 2005, 23:9583.
20. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004, 23:1448-1456. 10.1038/sj.onc.1207247, 14973554.
21. Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918. 10.1158/0008-5472.CAN-05-0530, 16061675.
22. Nasreen N, Mohammed KA, Antony VB. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 2006, 107:2425-2435. 10.1002/cncr.22254, 17041885.
23. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 2005, 24:7859-7868. 10.1038/sj.onc.1208937, 16103880.
24. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008, 118:64-78. 2129239, 18079969, 10.1172/JCI33154.
25. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006, 169:279-293. 1698769, 16816380, 10.2353/ajpath.2006.050889.
26. Kikawa K, Vidale DR, Van Etten RL, Kinch MS. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 2002, 277:39274-39279. 10.1074/jbc.M207127200, 12167657.
27. Orsulic S, Kemler R. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 2000, 113:1793-1802.
28. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 1999, 10:629-638.
29. Marquardt T, Shirasaki R, Ghosh S, Andrews SE, Carter N, Hunter T, Pfaff SL. Coexpressed EphA receptors and ephrin-A ligands mediate opposing actions on growth cone navigation from distinct membrane domains. Cell 2005, 121:127-139. 10.1016/j.cell.2005.01.020, 15820684.
30. Noren NK, Pasquale EB. Paradoxes of the EphB4 receptor in cancer. Cancer Res 2007, 67:3994-3997. 10.1158/0008-5472.CAN-07-0525, 17483308.
31. Larsen AB, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, Poulsen HS. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 2007, 5:283-293. 10.1158/1541-7786.MCR-06-0321, 17374733.
32. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Ligation of EphA2 by ephrin-A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 2004, 320:1096-1102. 10.1016/j.bbrc.2004.06.054, 15249202.
33. Hu M, Carles-Kinch KL, Zelinski DP, Kinch MS. EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells. Mol Cancer Res 2004, 2:533-540.
34. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E, Wang B. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001, 3:527-530. 11331884, 10.1038/35074604.
35. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005, 8:111-118. 10.1016/j.ccr.2005.07.005, 16098464.
36. Guo H, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC, Wang B. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 2006, 66:7050-7058. 10.1158/0008-5472.CAN-06-0004, 16849550.
37. Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 2006, 8:815-825. 10.1038/ncb1438, 16862147.
38. Batlle E, Bacani J, Begthel H, Jonkeer S, Gregorieff A, Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H. EphB receptor activity suppresses colorectal cancer progression. Nature 2005, 435:1126-1130. 10.1038/nature03626, 15973414.
39. Cortina C, Palomo-Ponce S, Iglesias M, Fernandez-Masip JL, Vivancos A, Whissell G, Huma M, Peiro N, Gallego L, Jonkheer S, Davy A, Lloreta J, Sancho E, Batlle E. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 2007, 39:1376-1383. 10.1038/ng.2007.11, 17906625.
40. Batlle E, Henderson JT, Beghtel H, Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, Wetering M, Pawson T, Clevers H. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002, 111:251-263. 10.1016/S0092-8674(02)01015-2, 12408869.
41. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18.
42. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 1995, 268:567-569. 10.1126/science.7536959, 7536959.
43. McBride JL, Ruiz JC. EphrinA1 is expressed at sites of vascular development in the mouse. Mech Dev 1998, 77:201-204. 10.1016/S0925-4773(98)00142-7, 9831653.
44. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309. 10.1016/j.ccr.2005.09.005, 16226705.
45. Brantley-Sieders DM, Fang WB, Hicks D, Koyama T, Shyr Y, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005, 19:1884-1886.
46. Brantley-Sieders D, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 2004, 117:2037-2049. 10.1242/jcs.01061, 15054110.
47. Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ, Chen J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem 2008, 283:16017-16026. 10.1074/jbc.M709934200, 18387945.
48. Hunter SG, Zhuang G, Brantley-Sieders DM, Swatt W, Cowan CW, Chen J. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mmediated angiogenesis. Mol Cell Biol 26:4830-4842. 1489141, 16782872, 10.1128/MCB.02215-05.
49. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998, 93:741-753. 10.1016/S0092-8674(00)81436-1, 9630219.
50. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999, 13:295-306. 9990854, 10.1101/gad.13.3.295, 316426.
51. Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, McDonald DM, Yancopoulos GD. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 2001, 230:151-160. 10.1006/dbio.2000.0112, 11161569.
52. Shin D, Garcia-Cardena G, Hayashi S, Gerety S, Asahara T, Stavrakis G, Isner J, Folkman J, Gimbrone MA, Anderson DJ. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol 2001, 230:139-150. 10.1006/dbio.2000.9957, 11161568.
53. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA 2004, 101:5583-5588. 397426, 15067119, 10.1073/pnas.0401381101.
54. Martiny-Baron G, Korff T, Schaffner F, Esser N, Eggstein S, Marme D, Augustin HG. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 2004, 6:248-257. 1502094, 15153337, 10.1593/neo.03457.
55. Sawai Y, Tamura S, Fukui K, Ito N, Imanaka K, Saeki A, Sakuda S, Kiso S, Matsuzawa Y. Expression of ephrin-B1 in hepatocellular carcinoma: possible involvement in neovascularization. J Hepatol 2003, 39:991-996. 10.1016/S0168-8278(03)00498-7, 14642617.
56. Nagashima K, Endo A, Ogita H, Kawana A, Yamagishi A, Kitabatake A, Matsuda M, Mochizuki N. Adaptor protein Crk is required for ephrin-B1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells. Mol Biol Cell 2002, 13:4231-4242. 138629, 12475948, 10.1091/mbc.E02-04-0181.
57. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002, 62:2840-2847.
58. Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, Munyon K, Kifle G, Woods R, Langermann S, Kiener PA, Kinch MS. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res 2003, 63:7907-7912.
59. Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther 2007, 6:3208-3218. 10.1158/1535-7163.MCT-07-0200, 18089715.
60. Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch MS, Coats S, Kiener PA, Tice DA. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 2008, 68:22. 10.1158/0008-5472.CAN-08-1933, 18172292.
61. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006, 5:1708-1713.
62. Dobrzanski P, Hunter K, Jones-Bonlin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 2004, 64:910-919. 10.1158/0008-5472.CAN-3430-2, 14871820.
63. Cheng N, Brantley D, Liu H, Fanslow W, Cerretti DP, Reith AD, Jackson D, Chen J. Inhibition of VEGF-dependent multi-stage carcinogenesis by soluble EphA receptors. Neoplasia 2003, 5:445-456. 1502614, 14670182.
64. Koolpe M, Burgess R, Dail M, Pasquale EB. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem 2005, 280:17301-17311. 10.1074/jbc.M500363200, 15722342.
65. Chrencik JE, Brooun A, Recht MI, Nicola G, Davis LK, Abagyan R, Widmer H, Pasquale EB, Kuhn P. Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem 2007, 282:36505-36513. 10.1074/jbc.M706340200, 17897949.
66. Noberini R, Koolpe M, Peddibhotla S, Dahl R, Su Y, Cosford ND, Roth GP, Pasquale EB. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 2008, 283:29461-29472. 10.1074/jbc.M804103200, 18728010.
67. Salvucci O, de la Luz Sierra M, Martina JA, McCormick PJ, Tosato G. EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood 2006, 108:2914-2922. 1895526, 16840724, 10.1182/blood-2006-05-023341.
68. Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007, 110:1469-1477. 10.1002/cncr.22958, 17685394.
69. Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2004, 2:40. 535538, 15563374, 10.1186/1479-5876-2-40.
70. Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003, 63:4481-4489.
71. Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, Horn K, Batlle E, Coudreuse D, Haramis A, Tjon-Pon-Fong M, Moerer P, Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250. 10.1016/S0092-8674(02)01014-0, 12408868.
72. Mohinta S, Wu H, Chaurasia P, Watabe K. Wnt pathway and breast cancer. Front Biosci 2007, 12:4020-4033. 10.2741/2368, 17485355.
73. Chrencik JE, Brooun A, Recht MI, Kraus ML, Koolpe M, Kolatkar AR, Bruce RH, Martiny-Baron G, Widmer H, Pasquale EB, Kuhn P. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure 2006, 14:321-330. 10.1016/j.str.2005.11.011, 16472751.
74. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 2002, 277:46974-46979. 10.1074/jbc.M208495200, 12351647.